$WUXI APPTEC(02359.HK)

The research and development capabilities of top-tier American medical institutions are indeed strong, but China is catching up at an astonishingly fast pace with remarkable efficiency.

More importantly, China possesses a vast number of real-world clinical cases, coupled with the systematic data accumulation and overall management advantages of its top-tier hospitals. Within a few years, in terms of both new drug development and overall treatment capabilities, China's leading hospitals will surprise many people.

It's like TSMC around the year 2000, where yield rates were painstakingly improved one wafer at a time.​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​